Writing stories of life

to advance science

News

12.12.2024 | Company News

Neurimmune and AICURA Announce Strategic Collaboration to Leverage AI for the Development of Alzheimer’s Disease Therapeutics

23.10.2024 | Company News

Neurimmune Announces Publication in Clinical Pharmacology & Therapeutics of The Prediction of Cardiac ATTR Depletion by ALXN2220

14.10.2024 | Company News

FDA Fast Track Designation for ALXN2220 for Depletion of Cardiac ATTR

27.08.2024 | Company News

Long-term safety and efficacy of antibody ALXN2220 for depletion of cardiac ATTR to be presented at ESC Congress 2024

23.05.2024 | Company News

Multiple Poster Presentations on ALXN2220 for Cardiac ATTR Amyloid Depletion to be Presented at the XIX International Symposium on Amyloidosis

09.05.2024 | Company News

Analysis of Initial Safety of Targeted Immune Activation and Predictive PK/PD Modeling for ALXN2220 to be presented at the Heart Failure 2024 Congress

04.04.2024 | Company News

Initiation of a Phase 3 Study of ALXN2220 for the Treatment of Transthyretin-mediated Amyloid Cardiomyopathy

06.03.2024 | Company News

Donald L. Price Memorial Lecture on Cryo-EM Structures of Disease Filaments from Human Brains to be presented at AD/PD 2024

31.01.2024 | Press Release

Neurimmune to regain global rights to brain amyloid depleter for the treatment of Alzheimer’s disease

12.10.2023 | Company News

Neurimmune Announces Publication in Nature Communications of its Experimental Therapy Depleting Pathologic IAPP Aggregates to Protect Beta Cell Health

20.05.2023 | Press Release

Promising Phase 1 results for antibody NI006 in ATTR cardiomyopathy published in The New England Journal of Medicine

17.05.2023 | Company News

Primary Results of the Phase 1b Proof-of-Concept Study of NI006 to be presented at the ESC Heart Failure Congress 2023

25.11.2022 | Company News

Keynote on the Therapeutic Reversal of Amyloid and Tau Pathology in Alzheimer’s Disease to be presented at the 15th Clinical Trials on Alzheimer’s Disease (CTAD) conference

01.03.2022 | Company News

Neurimmune and AstraZeneca close exclusive global collaboration and license agreement to develop and commercialize NI006

17.02.2022 | Company News

Alfred W. Sandrock, Jr. appointed to Neurimmune’s Board of Directors

Previous
1
2
3
4
Next

Your web browser is out of date

Update your browser for more security, speed and the best experience.

Update my browser Continue